We might just be able to see an end to the Human Immunodeficiency Virus, known as HIV in a few short years since the Oregon Health Sciences University have developed an HIV vaccine that could run for human trials by 2017.
A vaccine typically contains an agent to killed forms of the microbe, includes a weakened version of the virus so that it prepares your body’s immune system for such actual infection. Scientists, with HIV, took a slightly different approach by taking the cytomegalovirus(CMV) and used it as a backbone to carry fragment of HIV.
CMV utilized by this feat of engineering as a medium for immunization because it is a type of herpes virus that infects over 50 to 70 percent of Americans without any causes of disease.
It will be a harmless but active virus that would alert body’s immune system and generate antibodies for prolonged immunity against HIV. Researchers tested the experimental vaccine for trials using RhCMV — a strain of the virus that infects rhesus macaques, which allowed them to verify if the vaccine was effective against the monkey’s simian immunodeficiency virus (SIV), form of the AIDS virus.
60% of tested rhesus macaques were immunized against infection with SIV; a ground-breaking level of success for potential HIV or SIV vaccine, the Oregon National Primate Research Center reported.